Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490021 | 1.00 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL13767380 | 1.00 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL30111928 | 1.00 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL2490017 | 1.00 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL2180252 | 1.00 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL2180249 | 1.00 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| Carbamic Acid SCHEMBL4770752 | 0.94 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL4765504 | 0.92 | BTK (0.42) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL14040699 | 0.92 | BTK (0.42) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL14131624 | 0.92 | BTK (0.42) | BTKGAAEPHX1EPHX2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163016-A1 | PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2025-05-22 | — | — | US | disclosed |
| EP-4467537-A1 | PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) | 2024-11-27 | — | — | EP | disclosed |
| CN-117417348-A | Bergamot alcohol derivative and application thereof | 中国人民解放军海军军医大学 | 2024-01-19 | — | — | CN | disclosed |
| CN-117343050-A | Baicalein derivative and application thereof | 中国人民解放军海军军医大学 | 2024-01-05 | — | — | CN | disclosed |
| CN-117343085-A | Psoralen derivative and application thereof | 中国人民解放军海军军医大学 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023142641-A1 | PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都苑东生物制药股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023142641-A1 | PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都苑东生物制药股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-4182032-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-05-24 | — | — | EP | disclosed |
| US-20230125481-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| CN-115835910-A | Hydrogenated isoquinoline or naphthyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-1963324-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008006648-A1 | SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007122258-A1 | TRYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| WO-2007071936-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
| EP-1578743-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1578743-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163016-A1 | PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | KDM1B, KDM1A, EZH2 | BTK 2575/4885GAA 1765/4885EPHX1 1709/4885 |
| US-20070185153-A1 | COMPOUNDS | NRDC, NISCH, MRPL21 | BTK 3403/4885GAA 1443/4885EPHX1 3626/4885 |
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | BTK 3378/4885GAA 314/4885EPHX1 3422/4885 |
| US-20230125481-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | CRHR2, CRHR1, CRH | BTK 4504/4885GAA 2680/4885EPHX1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.